Taysha Gene Therapies (TSHA) Asset Writedowns and Impairment (2023 - 2024)
Taysha Gene Therapies (TSHA) reported Asset Writedowns and Impairment of $4.8 million for Q3 2024, up 685.39% on a YoY basis from $616000.0 in Q4 2023, and up 977.51% sequentially from $449000.0 in Q4 2023.
Taysha Gene Therapies (TSHA) Asset Writedowns and Impairment (2023 - 2024) Analysis & Trends
Taysha Gene Therapies (TSHA) has 2 years of Asset Writedowns and Impairment data on file, last reported at $4.8 million in Q3 2024.
- For the quarter ending Q3 2024, Asset Writedowns and Impairment rose 685.39% year-over-year to $4.8 million; the trailing twelve-month figure through Dec 2025 stood at $4.8 million (down 18.04% YoY), and the FY2024 full-year result was $4.8 million, up 354.27% from the prior year.
- Asset Writedowns and Impairment improved to $4.8 million in Q3 2024, from $449000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $4.8 million in Q3 2024 to a low of $449000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Taysha Gene Therapies | 2.05 Bn | 2.05 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 4.84 Mn |
| Sep 30, 2024 | 4.84 Mn |
| Dec 31, 2023 | 449,000.00 |
| Dec 31, 2023 | 449,000.00 |
| Sep 30, 2023 | 616,000.00 |
| Sep 30, 2023 | 616,000.00 |